TY - JOUR
T1 - IgG-mediated anaphylaxis to a Synthetic long peptide vaccine containing a B cell epitope can be avoided by slow-release formulation
AU - Quakkelaar, Esther D.
AU - Fransen, Marieke F.
AU - van Maren, Wendy W. C.
AU - Vaneman, Joost
AU - Loof, Nikki M.
AU - van Heiningen, Sandra H.
AU - Verbeek, J. Sjef
AU - Ossendorp, Ferry
AU - Melief, Cornelis J. M.
PY - 2014
Y1 - 2014
N2 - Synthetic long peptides (SLP) are a promising vaccine modality to induce therapeutic T cell responses in patients with chronic infections and tumors. We studied different vaccine formulations in mice using SLP derived from carcinoembryonic Ag. We discovered that one of the SLP contains a linear Ab epitope in combination with a CD4 epitope. Repeated vaccination with this carcinoembryonic Ag SLP in mice shows improved T cell responses and simultaneously induced high titers of peptide-specific Abs. These Abs resulted in unexpected anaphylaxis after a third or subsequent vaccinations with the SLP when formulated in saline. Administration of low SLP doses in the slow-release vehicle IFA prevented the anaphylaxis after repeated vaccination. This study underscores both the immunogenicity of SLP vaccination, for inducing T cell as well as B cell responses, and the necessity of safe administration routes. Copyright © 2014 by The American Association of Immunologists, Inc. 0022-1767/14/$16.
AB - Synthetic long peptides (SLP) are a promising vaccine modality to induce therapeutic T cell responses in patients with chronic infections and tumors. We studied different vaccine formulations in mice using SLP derived from carcinoembryonic Ag. We discovered that one of the SLP contains a linear Ab epitope in combination with a CD4 epitope. Repeated vaccination with this carcinoembryonic Ag SLP in mice shows improved T cell responses and simultaneously induced high titers of peptide-specific Abs. These Abs resulted in unexpected anaphylaxis after a third or subsequent vaccinations with the SLP when formulated in saline. Administration of low SLP doses in the slow-release vehicle IFA prevented the anaphylaxis after repeated vaccination. This study underscores both the immunogenicity of SLP vaccination, for inducing T cell as well as B cell responses, and the necessity of safe administration routes. Copyright © 2014 by The American Association of Immunologists, Inc. 0022-1767/14/$16.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84902127858&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/24813207
U2 - https://doi.org/10.4049/jimmunol.1302337
DO - https://doi.org/10.4049/jimmunol.1302337
M3 - Article
C2 - 24813207
SN - 0022-1767
VL - 192
SP - 5813
EP - 5820
JO - Journal of Immunology
JF - Journal of Immunology
IS - 12
ER -